CAS Number58-46-8
Synonyms2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; 9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isochinolin-2-on; tetrabenazine; Ro 1-9569; Rubigen; 3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; Nitoman
Molecular FormulaC19H27NO3
Molecular Weight317.42
Purity≥98 (HPLC)%
Density1.1±0.1 g/cm3
Boiling Point448.9±45.0 °C at 760 mmHg
Melting Point128-130ºC
Appearancesolid
EINECS200-383-6
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 58-46-8 |
| Catalog No. | 2A-9016780 |
| Chinese Name | 丁苯那嗪 |
| Synonyms | 2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; 9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isochinolin-2-on; tetrabenazine; Ro 1-9569; Rubigen; 3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; Nitoman |
| Molecular Formula | C19H27NO3 |
| Molecular Weight | 317.42 |
| Purity | ≥98 (HPLC) |
| Density | 1.1±0.1 g/cm3 |
| Boiling Point | 448.9±45.0 °C at 760 mmHg |
| Melting Point | 128-130ºC |
| Appearance | solid |
| Storage Condition | 0-10°C; store in inert gas; avoid air, heat |
| Packaging | III |
| Application | Tetrabenazine is a VMAT inhibitor that can act on hyperkinetic movement disorders. |
| EINECS | 200-383-6 |
| HTC | 2933990090 |
| PubChem ID | 329826731 |
| MDL Number | MFCD08461052 |
| SMILES | COc1cc2CCN3C[C@@H](CC(C)C)C(=O)CC3c2cc1OC |
| InChI | 1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1 |
| InChI Key | MKJIEFSOBYUXJB-GDBMZVCRSA-N |
| Beilstein/REAXYS | 40090 |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | 6.1(b) |
| Risk Codes | R22 |
| MSDS | msds/16780_1_58_46_8.pdf |
| Bioactivity | Tetrabenazine is a VMAT-inhibitor used for treatment of hyperkinetic movement disorder.Target: Otherstetrabenazine (TBZ), a monoamine-depleting and a dopamine-receptor-blocking drug. TBZ is an effective and safe drug for the treatment of a variety of hyperkinetic movement disorders. In contrast to typical neuroleptics, TBZ has not been demonstrated to cause tardive dyskinesia [1, 2]. Twenty patients with tardive dyskinesia (mean duration = 43.7 months) were videotaped before and after tetrabenazine treatment. One patient did not tolerate tetrabenazine owing to sedation. The remaining 19 were rated after a mean of 20.3 weeks at a mean tetrabenazine dose of 57.9 mg/day. There were significant improvements in mean scores on both the patient AIMS self-rating and the AIMS motor subset evaluated by the blind videotape raters. All 19 patients continued to take tetrabenazine after the study [3]. Related Catalog Signaling Pathways >> Membrane Transporter/Ion Channel >> Monoamine Transporter Research Areas >> Neurological Disease References [1]. Jankovic, J. and J. Beach, Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology, 1997. 48(2): p. 358-62. [2]. Kenney, C., C. Hunter, and J. Jankovic, Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord, 2007. 22(2): p. 193-7. [3]. Ondo, W.G., P.A. Hanna, and J. Jankovic, Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry, 1999. 156(8): p. 1279-81. Chemical & Physical Properties Density 1.1±0.1 g/cm3 Boiling Point 448.9±45.0 °C at 760 mmHg Melting Point 128-130ºC Molecular Formula C19H27NO3 Molecular Weight 317.423 Flash Point 225.3±28.7 °C Exact Mass 317.199097 PSA 38.77000 LogP 3.48 Vapour Pressure 0.0±1.1 mmHg at 25°C Index of Refraction 1.554 |
| Use of | Properties Articles51 Name 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Synonym More Synonyms Tetrabenazine Biological Activity Related Catalog Signaling Pathways >> Membrane Transporter/Ion Channel >> Monoamine Transporter Research Areas >> Neurological Disease References [1]. Jankovic, J. and J. Beach, Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology, 1997. 48(2): p. 358-62. [2]. Kenney, C., C. Hunter, and J. Jankovic, Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord, 2007. 22(2): p. 193-7. [3]. Ondo, W.G., P.A. Hanna, and J. Jankovic, Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry, 1999. 156(8): p. 1279-81. Chemical & Physical Properties Molecular Formula C19H27NO3 Exact Mass 317.199097 PSA 38.77000 Index of Refraction 1.554 |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: inconsistent with United Nations classification standards UN number: not specified Tetrabenazine Modification Number: 4 |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Aminophenazone | 58-15-1 | 2A-9016767 |
| Dypyridamole | 58-32-2 | 2A-9016774 |
| 10,10-Oxybisphenoxarsine | 58-36-6 | 2A-9016776 |
| Aminopromazine | 58-37-7 | 2A-9016777 |
| Promazine | 58-40-2 | 2A-9016779 |
| Angiotensin acetate | 58-49-1 | 2A-9016781 |
| Diphenhydramine | 58-73-1 | 2A-9016790 |
| D(+)-Xylose | 58-86-6 | 2A-9016793 |
| Lindane | 58-89-9 | 2A-9016794 |
| D-alpha-Tocopheryl acetate | 58-95-7 | 2A-9016797 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS